WebFeb 16, 2024 · LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat … WebJul 20, 2024 · Published: Jul 20, 2024. IRVINE, Calif., July 20, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc ., a clinical stage biopharmaceutical company developing first-in-class …
Did you know?
WebAug 1, 2016 · IRVINE, Calif., Aug. 1, 2016 /PRNewswire/ -- Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer, announced today that it has raised $13 million in its … WebFeb 16, 2024 · LA JOLLA, California, February 16, 2024 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage …
WebMar 24, 2024 · IRVINE, Calif., March 24, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in …
WebMar 24, 2024 · IRVINE, Calif., March 24, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, announced today the appointment of Alexandre Kaoukhov, M.D., as Senior … WebNov 5, 2024 · IRVINE, Calif., Nov. 5, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc. ("Bioniz") today announced an oral presentation at the 62nd ASH Annual Meeting and Exposition of positive safety and efficacy data from the company's Phase 1/2 clinical study of BNZ-1 for the treatment of refractory cutaneous T-cell lymphoma (rCTCL), a rare, …
WebConsidering the possession and an avid exhibition of the aforesaid traits, Dr. Nazli Azimi, the founder and CEO of Bioniz Therapeutics, Inc., has been recognized as one of the most inspirational women in tech. Her career commenced at the National Institutes of Health (NIH), which is the world’s largest biomedical research organization.
WebJul 20, 2024 · IRVINE, Calif., July 20, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancers, today announced encouraging interim clinical data from its Phase … ipeace incWebBioniz Therapeutics, Inc. develops biopharmaceuticals. The Company offers peptide therapeutics to treat immuno-inflammatory diseases and cancer. Bioniz Therapeutics … ipe300 beamsWebPhone Number (949)273-6000. Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of … ipeace reprogrammingWebBioniz Therapeutics. Pharmaceuticals · California, United States · <25 Employees . Bioniz Therapeutics is a clinical-stage biopharmaceutical company. It develops novel therapeutics to treat severe autoimmune and inflammatory. The company was established in 2009 and is based in Irvine, California. Read More. Contact ipea act explanatory memorandumWebBioniz is a biopharmaceutical company leading the discovery and development of multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases. Bioniz leverages expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to create a ... open vs closed primaries definitionWebWriting, no viable Mac OS X malware has emerged. You see it in soldiers, pilots, loggers, athletes, cops, roofers, and hunters. People are always trying to trick and rob you by … ipe agedWebMay 17, 2024 · Nazli Azimi is the founder and CEO of Bioniz Therapeutics, Inc., a biotech developing anti-cytokine therapies targeting oncology and autoimmune diseases.. Bioniz is building a pipeline of novel peptide therapeutics which selectively inhibit functionally redundant cytokines, while leaving the rest of the cytokine network unaffected. open vs. closed mri